Phase Ib Trial With Dose Expansion of the Bruton‟s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
- Indications Diffuse large B cell lymphoma; Nervous system neoplasms
- Focus Adverse reactions
- 22 Jan 2019 Status changed from not yet recruiting to recruiting.
- 15 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 04 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.